ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses8.61 M7.6 M9.02 M8.56 M7.88 M33.07 MResearch & development18.73 M12.88 M16.09 M14.52 M13.33 M56.83 MOperating income-27.35 M-20.37 M-25.05 M-23.08 M-21.21 M-89.72 MNon-Operating Income, Total-1.69 M-3.6 M2.51 M-4.15 M-1.6 M-6.84 MInterest expense, net of interest capitalized000000Non-Operating Income, excl. Interest Expenses-1.11 M-1.69 M2.51 M-3.45 M342.63 K-2.29 MUnusual income/expense-579.82 K-1.91 M-482-703.18 K-1.94 M-4.55 MPretax income-29.04 M-107.25 M-22.54 M-27.23 M-22.81 M-179.84 MEquity in earnings5.02 M—————Taxes—3.21 M————Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-25.17 M-19.38 M-19.69 M-23.52 M-45.5 M-108.09 MDiscontinued operations——————Net income-25.17 M-19.38 M-19.69 M-23.52 M-45.5 M-108.09 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-25.17 M-19.38 M-19.69 M-23.52 M-45.5 M-108.09 MBasic earnings per share (Basic EPS)-0.89-0.56-0.51-0.61-0.87-2.55Diluted earnings per share (Diluted EPS)-0.89-0.56-0.51-0.61-0.87-2.55Average basic shares outstanding28.14 M27.16 M38.61 M38.83 M52.17 M156.77 MDiluted shares outstanding28.14 M27.16 M38.61 M38.83 M52.17 M156.77 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)419.31 K464.67 K371.37 K356.15 K350.2 K1.54 M
Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.